Since 2004 the National Institute of Health and Clinical Excellence requires manufacturers to conduct a probabilistic sensitivity analysis for their technology appraisals. The objective of this review is to assess the outcomes of different probabilities of being cost effective and compare this with the actual decision making done by NICE.